



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Delgocitinib

Item No. 38307

CAS Registry No.: 1263774-59-9
Formal Name: (3S,4R)-3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane-1-propanenitrile
Synonym: JTE-052
MF: C₁₆H₁₈N₆O
FW: 310.4
Purity: ≥98%
UV/Vis.: λ_{max}: 214, 285 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Delgocitinib is supplied as a solid. A stock solution may be made by dissolving the delgocitinib in the solvent of choice, which should be purged with an inert gas. Delgocitinib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of delgocitinib in these solvents is approximately 30 mg/ml.

Description

Delgocitinib is an inhibitor of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2; IC₅₀s = 2.8, 2.6, 13, and 58 nM, respectively).¹ It is selective for JAK1, JAK2, JAK3, and TYK2 over lymphocyte cell-specific tyrosine kinase (LCK; IC₅₀ = 5,800 nM). Delgocitinib inhibits IL-31-induced increases in STAT3 phosphorylation levels in A549 cells (IC₅₀ = 25 nM). It reduces IL-31-induced scratching in mice in a dose-dependent manner.² Formulations containing delgocitinib have been used in the treatment of atopic dermatitis.

References

1. Noji, S., Hara, Y., Miura, T., *et al.* Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. *J. Med. Chem.* **63**(13), 7163-7185 (2020).
2. Yamamoto, Y., Otsuka, A., Nakashima, C., *et al.* Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. *J. Dermatol. Sci.* **97**(2), 161-164 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM